The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:
- Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
- What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?
People
Related Insights
19 September 2024
Viewpoints
SEC’s Focus on Whistleblower Protection Practices Continues
On September 9, 2024, the U.S. Securities and Exchange Commission announced that it settled charges against seven public companies for alleged violations of Securities Exchange Act Rule 21F-17.
19 September 2024
Manufacturing Industry Advisor
Cybersecurity in the Age of Industry 4.0 – Part 2
This is the second article in our two-part series on Cybersecurity in the Age of Industry 4.0, focusing on the legal implications and potential liabilities manufacturers face from cyberattacks, as well as practical recommendations to mitigate these risks.
19 September 2024
Viewpoints
FINRA In-House Disciplinary Proceedings Survive Post-Jarkesy Challenge … For Now
On September 4, 2024, the United States District Court for the Eastern District of Pennsylvania denied D. Allen Blankenship’s challenge to enjoin the Financial Industry Regulatory Authority’s disciplinary action against him.